cetuximab   Click here for help

GtoPdb Ligand ID: 6882

Synonyms: C225 | Erbitux® | IMC-225 | IMC-C225
Approved drug
cetuximab is an approved drug (Switzerland (2003), EMA & FDA (2004))
Compound class: Antibody
Comment: Cetuximab binds to and competitively inhibits the activity of the epidermal growth factor receptor (EGFR).
Annotated peptide sequences for this antibody are available from its IMGT/mAb-DB record.

As Bristol-Myers Squibb's original EU and US patents for cetuximab have expired, challengers of cetuximab's market position are developing biosimilar and/or biobetter cetuximab.
Celltrion's CT-P15 is a cetuximab biosimilar, intended for the treatment of colorectal cancer. MabTech-Sorrento's STI-001 is a proposed biobetter cetuximab (perhaps because synthesis in CHO cells creates a different glycosylation pattern to that of cetuximab which is made in mouse cells, and may be less likely to cause side-effects such as immunogenicity and hypersensitivity). STI-001 has completed Phase 3 clinical trial in China. Neither of these agents is associated with any clinical studies that are registered with ClinicalTrials.gov.
Click here for help
No information available.
Summary of Clinical Use Click here for help
Used to treat EGFR-expressing metastatic colorectal cancer where other chemotherapies have failed to show response. Also used to treat head and neck cancers of squamous cell origin, in combination with radiotherapy.
External links Click here for help